Biovaxys Technology Corp

BioVaxys Technology Corp. is a clinical stage biotechnology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-11-21. The firm is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergies, and other immunological diseases. The firm's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers and also delivers an innate immune activator and a universal CD4 T cell helper peptide.